PE20020229A1 - COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE - Google Patents
COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACEInfo
- Publication number
- PE20020229A1 PE20020229A1 PE2001000327A PE2001000327A PE20020229A1 PE 20020229 A1 PE20020229 A1 PE 20020229A1 PE 2001000327 A PE2001000327 A PE 2001000327A PE 2001000327 A PE2001000327 A PE 2001000327A PE 20020229 A1 PE20020229 A1 PE 20020229A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- hmg
- combination
- receptor
- coa reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE UNA COMBINACION DE AL MENOS UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II AT1 TAL COMO VALSARTAN, LOSARTAN, CANDESARTAN, EPROSARTAN, IRBESARTAN, SAPRISARTAN, TASOSARTAN, TELMISARTAN O UN ANTAGONISTA DEL RECEPTOR AT1 COMBINADO CON UN DIURETICO; UN INHIBIDOR DE HMG-CoA REDUCTASA COMO ATORVASTATINA, CERIVASTATINA, FLUVASTATINA, LOVASTATINA, PITAVASTATINA, PROVASTATINA, ROSUVASTATINA, SIMVASTATINA; UN INHIBIDOR DE ACE COMO ALACEPRIL, BENAZEPRIL, CAPTOPRIL, CERONAPRIL, CILAZAPRIL, DELAPRIL, ENALAPRIL, ENAPRILAT, FOSINOPRIL, IMIDAPRIL, LISINOPRIL, MOVELTOPRIL, QUINALAPRIL, ENTRE OTROS; PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE HIPERLIPIDEMIA, DISLIPIDEMIA, ATEROSCLEROSIS, RESISTENCIA DE INSULINA, SINDROME X, DIABETES MELLITUS TIPO 2, OBESIDA, NEFROPATIA, INSUFICIENCIA RENAL, HIPOTIROIDISMO, DISFUNCION ENDOTELIAL CON O SIN HIPERTENSION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19674300P | 2000-04-12 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020229A1 true PE20020229A1 (es) | 2002-04-11 |
Family
ID=22726659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000327A PE20020229A1 (es) | 2000-04-12 | 2001-04-10 | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040023840A1 (es) |
| EP (1) | EP1326604A2 (es) |
| JP (1) | JP2003530342A (es) |
| KR (1) | KR20020089433A (es) |
| CN (2) | CN1651087A (es) |
| AR (1) | AR032152A1 (es) |
| AU (1) | AU2001258323A1 (es) |
| BR (1) | BR0109966A (es) |
| CA (1) | CA2405793A1 (es) |
| CZ (1) | CZ20023381A3 (es) |
| HU (1) | HUP0400475A3 (es) |
| IL (1) | IL152079A0 (es) |
| MX (1) | MXPA02010090A (es) |
| NO (1) | NO20024921L (es) |
| PE (1) | PE20020229A1 (es) |
| PL (1) | PL365696A1 (es) |
| RU (1) | RU2298418C2 (es) |
| SK (1) | SK14642002A3 (es) |
| WO (1) | WO2001076573A2 (es) |
| ZA (1) | ZA200208203B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| SK18062002A3 (sk) * | 2000-06-22 | 2003-07-01 | Novartis Ag | Pevné orálne farmaceutické kompozície obsahujúce valsartan |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| ATE511395T1 (de) * | 2001-04-19 | 2011-06-15 | Kowa Co | Mittel zur behandlung von glomerulopathie |
| US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| EP1579872B8 (en) | 2002-12-27 | 2012-11-07 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
| GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| EP1818056A1 (de) * | 2003-01-16 | 2007-08-15 | Boehringer Ingelheim International Gmbh | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| WO2004096276A1 (ja) * | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | 糖取り込み能増強剤 |
| EP1621210B1 (en) * | 2003-04-28 | 2013-06-19 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
| TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
| AU2008201290B2 (en) * | 2003-09-26 | 2010-12-09 | Astrazeneca Uk Limited | Therapeutic treatment |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| RU2006125512A (ru) * | 2003-12-16 | 2008-01-27 | Новартис АГ (CH) | Применение статинов для лечения метаболического синдрома |
| PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
| WO2006046528A1 (ja) * | 2004-10-29 | 2006-05-04 | Kowa Co., Ltd. | 糸球体疾患治療剤 |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
| KR101436644B1 (ko) * | 2006-01-31 | 2014-09-01 | 코와 가부시키가이샤 | 당뇨병 치료제 |
| FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
| GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
| CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| RU2505297C1 (ru) * | 2012-11-21 | 2014-01-27 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Средство для медикаментозной коррекции нарушений нитроксидергической системы |
| BR112015026219B1 (pt) * | 2013-05-13 | 2021-12-21 | Macro Plastic, Inc | Contentor de remessa |
| BR102013028883A2 (pt) * | 2013-11-08 | 2015-10-06 | Hypermarcas S A | forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica |
| MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
| BR9604818A (pt) * | 1995-04-07 | 1998-06-09 | Novartis Ag | Composições de combinação contendo benazepril ou benazeprilat e valsartan |
| CA2224451A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
| UY24504A1 (es) * | 1996-03-29 | 1997-09-19 | Smithkline Beecham Corp | Dihidrato de eprosartano y un procedimiento para su produccion y formulacion |
| CZ299162B6 (cs) * | 1996-07-15 | 2008-05-07 | Sankyo Company, Limited | Farmaceutický prípravek a souprava |
-
2001
- 2001-04-10 CA CA002405793A patent/CA2405793A1/en not_active Abandoned
- 2001-04-10 MX MXPA02010090A patent/MXPA02010090A/es active IP Right Grant
- 2001-04-10 RU RU2002129558/15A patent/RU2298418C2/ru not_active IP Right Cessation
- 2001-04-10 IL IL15207901A patent/IL152079A0/xx unknown
- 2001-04-10 PE PE2001000327A patent/PE20020229A1/es not_active Application Discontinuation
- 2001-04-10 PL PL01365696A patent/PL365696A1/xx not_active Application Discontinuation
- 2001-04-10 CZ CZ20023381A patent/CZ20023381A3/cs unknown
- 2001-04-10 CN CNA2004101012182A patent/CN1651087A/zh active Pending
- 2001-04-10 HU HU0400475A patent/HUP0400475A3/hu unknown
- 2001-04-10 AU AU2001258323A patent/AU2001258323A1/en not_active Abandoned
- 2001-04-10 EP EP01931583A patent/EP1326604A2/en not_active Withdrawn
- 2001-04-10 JP JP2001574091A patent/JP2003530342A/ja active Pending
- 2001-04-10 US US10/257,559 patent/US20040023840A1/en not_active Abandoned
- 2001-04-10 SK SK1464-2002A patent/SK14642002A3/sk unknown
- 2001-04-10 WO PCT/EP2001/004115 patent/WO2001076573A2/en active Application Filing
- 2001-04-10 BR BR0109966-3A patent/BR0109966A/pt not_active IP Right Cessation
- 2001-04-10 CN CN01807919A patent/CN1440283A/zh active Pending
- 2001-04-10 AR ARP010101697A patent/AR032152A1/es not_active Application Discontinuation
- 2001-04-10 KR KR1020027013336A patent/KR20020089433A/ko not_active Application Discontinuation
-
2002
- 2002-10-11 NO NO20024921A patent/NO20024921L/no not_active Application Discontinuation
- 2002-10-11 ZA ZA200208203A patent/ZA200208203B/en unknown
-
2006
- 2006-10-31 US US11/590,215 patent/US20070105894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400475A3 (en) | 2006-02-28 |
| NO20024921D0 (no) | 2002-10-11 |
| ZA200208203B (en) | 2003-11-07 |
| AU2001258323A1 (en) | 2001-10-23 |
| AR032152A1 (es) | 2003-10-29 |
| HUP0400475A2 (hu) | 2004-06-28 |
| NO20024921L (no) | 2002-11-07 |
| JP2003530342A (ja) | 2003-10-14 |
| IL152079A0 (en) | 2003-05-29 |
| US20070105894A1 (en) | 2007-05-10 |
| BR0109966A (pt) | 2003-08-05 |
| CA2405793A1 (en) | 2001-10-18 |
| CN1651087A (zh) | 2005-08-10 |
| SK14642002A3 (sk) | 2003-05-02 |
| MXPA02010090A (es) | 2003-02-12 |
| WO2001076573A3 (en) | 2003-04-17 |
| KR20020089433A (ko) | 2002-11-29 |
| US20040023840A1 (en) | 2004-02-05 |
| PL365696A1 (en) | 2005-01-10 |
| CZ20023381A3 (cs) | 2003-02-12 |
| EP1326604A2 (en) | 2003-07-16 |
| WO2001076573A2 (en) | 2001-10-18 |
| RU2298418C2 (ru) | 2007-05-10 |
| CN1440283A (zh) | 2003-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020229A1 (es) | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE | |
| CY1106813T1 (el) | Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης | |
| NZ701609A (en) | Liquid formulation comprising propylene glycol and an inodilator | |
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| AR079428A1 (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares | |
| EA200700765A1 (ru) | Двуслойная таблетка | |
| JP2003521437A5 (es) | ||
| WO2008051416A3 (en) | Compounds that inhibit the activity of hsp90 for treating infections | |
| PE20020082A1 (es) | Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) | |
| IL160643A (en) | Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit | |
| EP2127646A4 (en) | AGENT TO RELIEVE OR PREVENT XEROSOMY | |
| MY144857A (en) | Phamaceutical composition comprising amlodipine and losartan | |
| WO2009081169A3 (en) | Biodegradable contrast agents | |
| RS20080510A (en) | Benzimidazole derivative and use as angiotensin ii antagonist | |
| FR2934501B1 (fr) | Systeme de prevention des risques d'incendies | |
| RU2006135205A (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
| UA107967C2 (en) | Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan | |
| EP2420233A3 (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| RU2016126852A (ru) | Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы | |
| GR20050100466A (el) | Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| WO2006106358A3 (en) | Use of nk-3 receptor antagonists for the treatment of nausea and vomiting | |
| AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |